![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
20
Hetero Labs Limited Hyderabad In, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their significant offerings is Pioglitazone hydrochloride, supported by a 'Withdrawn by Holder' Certificate of Suitability (CEP) with the number R1-CEP 2012-363 - Rev 00
This Chemical Type CEP, issued on July 17, 2019, remains in force until July 30, 2019, ensuring its reliability within the pharmaceutical industry.
Substance Number 2601 associated with this CEP further emphasizes